|
|
|
|
|
1
|
Please note the Gantt chart is only an estimate and should be customized base on your specific modality, therapeutic area,
and intended clinical use.
Our scientific advisors are on hand to discuss your research and create a strategic plan that is unique to your program.
- Charles River is not committing to these dates at this time.
- Actual milestone dates would have to be confirmed by contacting us.
|
|
|
|
|
|
|
|
W - Weeks
|
Start date
|
End date
|
|
|
|
|
Start date
|
End date
|
|
|
1 Timelines are based on an optimized IND program to audited draft report.
They are subject to change and can be adapted on a case-by-case basis.
2 Includes 1-month long-term matrix stability.
3 Or relevant toxicology species. This timeline assumes that preliminary toxicology
data was collected during Lead Optimization Phase.
4 Can be incorporated as part of the definitive 28-day GLP studies, as
needed.
5 Timeline based on the use of non-naive animals (if available in-house).
If naive animals are required add 6 weeks prior to dosing for delivery, acclimation and surgical procedures.
1 Timelines are based on an optimized IND program to audited draft report.
They are subject to change and can be adapted on a case-by-case basis.
2 If bridging ECL, development can be done for both species under the
same method development study.
3 Possibility to use non-naive but biologically-naive animals if available in-house.
If naive animals are required, add 4-6 weeks for NHP acclimation and pretreatment time.
4 Safety pharmacology endpoints can be incorporated withing definitive studies.
|
|
|
|
|